GLP-1 Drugs Work. The Miracle Stories Are Making Them Dangerous
Evidence reviewed through October 30, 2026. This is reporting, not a personal prescription. Public GLP-1 debate has gone feral. One camp sells a weekly injection as absolution for having a body. Another camp insists that blindness and ruined genitals are the certain price for trying to lose weight. Both camps thrive when evidence gets flattened into a slogan. These drugs are powerful medicines with measured benefits, common side effects, serious rare risks, and unresolved questions about decades of use. They deserve neither worship nor panic. A patient deserves a calculation based on a diagnosis, a health history, and the exact product inside the pen. Drug names already cause trouble. Semaglutide is a GLP-1 receptor agonist. Tirzepatide activates GIP and GLP-1 receptors, so calling every shot a GLP-1 is convenient shorthand, not precise pharmacology. Ozempic and Wegovy contain semaglutide, yet their labeled uses and dosing differ. Mounjaro and Zepbound contain tirzepatide, with different labeled uses as well. A story about one product can become a story about all of them before breakfast. That confusion lets people borrow reassurance from a diabetes trial or borrow terror from an unverified report about another drug.

Continue reading → GLP-1 Drugs Work. The Miracle Stories Are Making Them Dangerous
You must be logged in to post a comment.